US spot XRP ETFs attracted $4.25 million in net inflows last week, reversing a $1.84 million outflow the prior week that ended a 13-week streak. This inflow occurred despite Bitcoin, Ethereum, and Solana ETFs experiencing net outflows, highlighting a unique investor interest in XRP. Franklin Templeton's XRPZ fund led the inflows, suggesting institutional interest, while Bitwise's XRP ETF showed neutral activity. Overall, XRP ETFs have accumulated about $1.8 billion since November 2025, but the token price remains below $1.40 resistance, indicating inflows have not yet driven a price recovery.
The recent US spot XRP ETFs inflows provide context for cryptocurrency market activity on Pluang. For readers following crypto assets, here is Pluang's market snapshot as of Oct 26, 2026 17:21 WIB: out of 50 major cryptocurrencies, 26 rose and 22 fell today. Notably, SXP (Solar) dropped sharply by 46.27% to Rp37 with a typical hold time of 94 days, while BAL (Balancer) gained 11.14% to Rp16,297 with a hold time of 85 days. COMP (Compound) declined 9.90% to Rp376,628, with Pluang order activity showing 31% Sell and 69% Buy, and a typical hold time of 98 days.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
